Quantum Biopharma (QNTM) Total Non-Current Liabilities (2020 - 2026)
Quantum Biopharma (QNTM) reported Total Non-Current Liabilities of $11.0 million for Q1 2026, up 46.97% on a YoY basis from $7.5 million in Q1 2025, and up 82.03% sequentially from $6.1 million in Q4 2025.
Quantum Biopharma (QNTM) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 7 years of Total Non-Current Liabilities data on file, last reported at $11.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 46.97% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (up 46.97% YoY), and the FY2025 full-year result was $6.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $11.0 million in Q1 2026, from $6.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $11.0 million in Q1 2026 to a low of -$522884.0 in Q1 2022.
- A 5-year average of $3.1 million and a median of $1.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities slumped 99.53% in 2022 and soared 4223.27% in 2024, its largest moves.
- Tracing QNTM's Total Non-Current Liabilities over 5 years: stood at $38004.0 in 2022, then plunged by 443.08% to -$130383.0 in 2023, then soared by 2923.19% to $3.7 million in 2024, then surged by 64.58% to $6.1 million in 2025, then soared by 82.03% to $11.0 million in 2026.
- Business Quant data shows QNTM's Total Non-Current Liabilities at $11.0 million in Q1 2026, $6.1 million in Q4 2025, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - | 11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.03 Mn |
| Dec 31, 2025 | 6.06 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Sep 30, 2023 | -130,383.00 |
| Jun 30, 2023 | -122,351.00 |
| Mar 31, 2023 | -450,544.00 |
| Dec 31, 2022 | 38,004.00 |
| Sep 30, 2022 | -388,481.00 |
| Jun 30, 2022 | -425,620.00 |
| Mar 31, 2022 | -522,884.00 |
| Dec 31, 2021 | 8.07 Mn |
| Sep 30, 2021 | -1.43 Mn |
| Jun 30, 2021 | -1.71 Mn |
| Mar 31, 2021 | -2.00 Mn |
| Dec 31, 2020 | 4.21 Mn |
| Sep 30, 2020 | -2.61 Mn |